Method for activating platelets to release growth factors and exosomes, electronic equipment and storage medium

Abstract

The embodiment of the invention provides a method for activating platelets to release growth factors and exosomes, electronic equipment and a storage medium, and the method comprises the following steps: determining a target activation mode of platelet-rich plasma based on a target application of the platelet-rich plasma; starting at least one of an illumination end, an ultrasonic end and a temperature control end of the electronic equipment based on the target activation mode; the platelet-rich plasma is irradiated on the basis of preset illumination parameters when the illumination end is turned on, and / or the platelet-rich plasma is subjected to ultrasonic treatment on the basis of preset ultrasonic parameters when the ultrasonic end is turned on, and / or the temperature of the environment where the platelet-rich plasma is located is adjusted on the basis of preset temperature control parameters when the temperature control end is turned on; the platelets are activated to release growth factors and exosomes. According to the embodiment of the invention, the exogenous activation of the platelets is realized by combining ultrasonic, illumination and temperature control physical methods, so that the platelets release exosomes while releasing growth factors, chemical reagents are not required to be introduced, and the human health is effectively guaranteed.

Description

Technical Field

[0001] This application relates to the field of blood processing technology, and in particular to a method, electronic device and storage medium for activating platelets to release growth factors and exosomes. Background Technology

[0002] Platelet-rich plasma (PRP) is a platelet concentrate prepared by centrifugation of autologous whole blood. It has a high platelet concentration and contains multiple growth factors such as platelet-derived growth factor (PDGF) and transforming growth factor β (TGF-β).

[0003] Platelet-rich plasma is typically activated exogenously in vitro before use to rapidly release growth factors. In vitro activation ensures that almost all platelets are degranulated before injection, facilitating the delivery of high concentrations of growth factors to the site of injury and avoiding the uncertainties associated with in vivo activation.

[0004] In related technologies, exogenous activation of platelets is mainly achieved through chemical methods, which trigger the platelet activation process by adding chemical reagents. However, the chemical reagents used in these methods may have adverse effects on the human body, thereby affecting human health. Summary of the Invention

[0005] In view of the above, it is necessary to provide a method, electronic device and storage medium for activating platelets to release growth factors and exosomes, to solve the problem that the exogenous activation of platelets is mainly achieved by chemical methods, but the chemical reagents used in chemical methods may have adverse effects on the human body and may affect human health.

[0006] In a first aspect, embodiments of this application provide a method for activating platelets to release growth factors and exosomes, applied to an electronic device, the method comprising: Based on the intended use of platelet-rich plasma, the target activation mode of the platelet-rich plasma is determined; Based on the target activation method, at least one of the light-emitting end, ultrasonic end, and temperature-control end of the electronic device is activated. When the light-emitting end is turned on, the platelet-rich plasma is irradiated based on preset light-emitting parameters, and / or when the ultrasound end is turned on, the platelet-rich plasma is subjected to ultrasound treatment based on preset ultrasound parameters, and / or when the temperature control end is turned on, the temperature of the environment in which the platelet-rich plasma is located is adjusted based on preset temperature control parameters, so that platelets are activated and release growth factors and exosomes.

[0007] In one possible implementation, the method further includes: Receive user input regarding the intended use of the platelet-rich plasma; The target activation method of the platelet-rich plasma is determined based on the user's input of the intended use of the platelet-rich plasma. The target activation method is determined from a plurality of preset activation methods, including light activation, ultrasound activation, temperature control activation, light and ultrasound activation, light and temperature control activation, ultrasound and temperature control activation, and light, ultrasound and temperature control activation.

[0008] In one possible implementation, determining the target activation mode of the platelet-rich plasma based on the user-inputted target use of the platelet-rich plasma includes: Based on the correspondence between the purpose and the preset activation method, and the target purpose, the preset activation method corresponding to the target purpose is determined, and the preset activation method corresponding to the target purpose is determined as the target activation method.

[0009] In one possible implementation, determining the target activation mode of the platelet-rich plasma based on the user-inputted target use of the platelet-rich plasma further includes: The target activation method is sent to the interactive terminal of the electronic device; The target activation method is displayed to the user for confirmation through the interactive terminal. If the user does not select the target activation method, the preset activation method input by the user is received. The user-input preset activation method is determined as the target activation method.

[0010] In one possible implementation, the preset illumination parameters include a preset wavelength, a preset light intensity range, and a preset irradiation duration. Irradiating the platelet-rich plasma based on the preset illumination parameters when the illumination end is turned on includes: Control the light source to emit light of the preset wavelength; The light intensity sensed by the light sensor of the electronic device is collected. If the light intensity sensed by the light sensor is not within the preset light intensity range, the wavelength of the light is adjusted until the light intensity sensed by the light sensor falls within the preset light intensity range. The preset irradiation time for irradiating the platelet-rich plasma by the light source is controlled.

[0011] In one possible implementation, the preset ultrasound parameters include a preset on-time, a preset frequency, and a preset duty cycle. The step of performing ultrasound processing on the platelet-rich plasma based on the preset ultrasound parameters when the ultrasound terminal is on includes: The ultrasound terminal is controlled to generate ultrasound waves based on the preset frequency and the preset duty cycle. The ultrasound waves propagate in the platelet-rich plasma for the preset on-time.

[0012] In one possible implementation, the preset temperature control parameter includes a first preset temperature range, and the step of adjusting the temperature of the platelet-rich plasma environment based on the preset temperature control parameter when the temperature control terminal is turned on includes: The temperature control terminal maintains the ambient temperature of the platelet-rich plasma within the preset temperature range.

[0013] In one possible implementation, the preset temperature control parameters include a second preset temperature range and a corresponding preset duration. If the target activation method includes a temperature control activation method, adjusting the temperature of the platelet-rich plasma environment based on the preset temperature control parameters when the temperature control terminal is turned on further includes: The temperature control terminal is used to maintain the ambient temperature of the platelet-rich plasma within the second preset temperature range for the preset duration. The temperature control terminal is heated to maintain the ambient temperature of the platelet-rich plasma within the first preset temperature range.

[0014] Secondly, embodiments of this application provide an electronic device, the electronic device including a memory and a processor: The memory is used to store program instructions; The processor is configured to read and execute the program instructions stored in the memory. When the program instructions are executed by the processor, the electronic device performs the above-described method of activating platelets to release growth factors and exosomes.

[0015] Thirdly, embodiments of this application provide a computer storage medium storing program instructions that, when executed on an electronic device, cause the processor of the electronic device to perform the aforementioned method of activating platelets to release growth factors and exosomes.

[0016] The method, electronic device, and storage medium for activating platelets to release growth factors and exosomes provided in this application embodiment can achieve exogenous activation of platelets based on physical methods combining ultrasound, light irradiation, and temperature control. This allows platelets to release exosomes while releasing growth factors, without the need to introduce chemical reagents, ensuring high safety and effectively protecting human health. Attached Figure Description

[0017] To more clearly illustrate the technical solutions in the embodiments of this application or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of this application. For those skilled in the art, other drawings can be obtained based on the provided drawings without creative effort.

[0018] Figure 1 This is a schematic diagram illustrating an application scenario of the method for activating platelets to release growth factors and exosomes provided in an embodiment of this application.

[0019] Figure 2 This is a flowchart of a method for activating platelets to release growth factors and exosomes according to an embodiment of this application.

[0020] Figure 3 This is a schematic diagram illustrating the method for determining target activation according to an embodiment of this application.

[0021] Figure 4 This is a schematic diagram of parameter control corresponding to the target activation method provided in an embodiment of this application.

[0022] Figure 5 This is a schematic diagram of the hardware structure of an electronic device provided in an embodiment of this application. Detailed Implementation

[0023] The terms "first" and "second" used in the embodiments of this application are for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of indicated technical features. Therefore, a feature defined as "first" or "second" may explicitly or implicitly include one or more features. In the description of the embodiments of this application, words such as "exemplary" or "for example" are used to indicate examples, illustrations, or descriptions. Any embodiment or design described as "exemplary" or "for example" in the embodiments of this application should not be construed as being more preferred or advantageous than other embodiments or designs. Specifically, the use of words such as "exemplary" or "for example" is intended to present the relevant concepts in a concrete manner.

[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application pertains. The terminology used in this application's specification is for the purpose of describing particular embodiments only and is not intended to limit the application. It should be understood that, unless otherwise stated, " / " in this application means "or". For example, A / B can mean A or B. "And / or" in this application is merely a description of the relationship between related objects, indicating that three relationships can exist. For example, A and / or B can represent: A alone, A and B simultaneously, and B alone. "At least one" refers to one or more. "More than one" refers to two or more. For example, at least one of a, b, or c can represent: a, b, c, a and b, a and c, b and c, and a, b, and c. Where there is no conflict, the following embodiments and features described herein can be combined with each other.

[0025] Platelet-rich plasma is a platelet concentrate prepared by centrifugation of autologous whole blood. Its platelet concentration can reach 4-8 times that of normal blood and contains multiple growth factors such as PDGF and TGF-β.

[0026] Platelet-rich plasma (PRP) is activated in vitro via chemical or physical means before use; this is called exogenous activation. Platelet activation leads to the rapid release of growth factors, including most of them. In vitro activation ensures that almost all platelets have completed degranulation before injection, delivering a high concentration of growth factors directly to the site of injury in a single dose, avoiding the uncertainties of in vivo activation.

[0027] In related technologies, exogenous activation of platelets is mainly achieved through chemical methods, which trigger the platelet activation process by adding chemical reagents such as calcium chloride and thrombin. However, the chemical reagents or protective agents used in chemical methods may have adverse effects on the human body, thereby affecting human health.

[0028] To address the issue that exogenous platelet activation is primarily achieved through chemical methods, which may have adverse effects on human health due to the potential harm caused by the chemical reagents used, this application provides a method for activating platelets to release growth factors and exosomes. This method utilizes physical methods combining ultrasound, light irradiation, and temperature control to achieve exogenous platelet activation, enabling platelets to release growth factors and exosomes simultaneously. This eliminates the need for chemical reagents, ensuring high safety and effectively protecting human health.

[0029] See Figure 1 The diagram shown illustrates an application scenario of a method for activating platelets to release growth factors and exosomes according to an embodiment of this application. This application provides an electronic device 1 for exogenously activating platelets to release growth factors and exosomes. The electronic device 1 includes, but is not limited to: a container 10, a light-emitting terminal 20, an ultrasound terminal 30, a temperature-control terminal 40, a control terminal 50, an execution terminal 60, and an interaction terminal 70.

[0030] The container 10 has an open end for holding platelet-rich plasma. The light-emitting end 20 is positioned above the container 10 to provide a light source for irradiating the platelet-rich plasma. The ultrasonic end 30 is located at the bottom or below the container 10 to generate ultrasonic waves that act on the platelet-rich plasma. For example, the ultrasonic end 30 can be an ultrasonic generator. The temperature control end 40 is located below or near the container 10 to regulate the ambient temperature of the platelet-rich plasma. For example, the temperature control end 40 can be an air conditioner, a heat exchanger, etc.

[0031] The control terminal 50 is used to determine the target activation mode of the platelet-rich plasma based on its intended use. The target activation mode is determined from a plurality of preset activation modes, including, but not limited to: light activation, ultrasound activation, temperature-controlled activation, light and ultrasound activation, light and temperature-controlled activation, ultrasound and temperature-controlled activation, and light, ultrasound, and temperature-controlled activation.

[0032] The execution terminal 60 is used to activate at least one of the light-emitting terminal 20, the ultrasound terminal 30, and the temperature-control terminal 40 based on the target activation mode to process the platelet-rich plasma, thereby activating platelets and releasing growth factors and exosomes. For example, the growth factors may be PDGF, TGF-β, etc., and the exosomes may include proteins, nucleic acids, lipids, etc. In one embodiment of this application, the control terminal 50 and the execution terminal 60 may be processors.

[0033] The interactive terminal 70 is used to receive the intended use of the platelet-rich plasma input by the user. For example, the interactive terminal 70 may be a touch screen.

[0034] The electronic device 1 may further include a memory ( Figure 1 (Not shown), the memory stores the plurality of preset activation methods and the correspondence between the preset activation methods and their uses. The control terminal 50 determines the preset activation method corresponding to the target use based on the correspondence between the use and the preset activation methods and the target use of the platelet-rich plasma input by the user, and determines the preset activation method corresponding to the target use as the target activation method.

[0035] In another embodiment of this application, the control terminal 50 also sends the target activation method to the interaction terminal 70, which displays the target activation method for user confirmation. For example, the target activation method is displayed via a pop-up window, which includes the options "Yes" and "No". If the user selects "No", that is, does not select the target activation method, the preset activation method input by the user is received. For example, after the user selects "No", the multiple preset activation methods are displayed in a list, with each preset activation method corresponding to an option, and the preset activation method selected by the user is determined based on the option selected by the user. The interaction terminal 70 sends the preset activation method input by the user to the control terminal 50, and the control terminal 50 is also used to determine the preset activation method input by the user as the target activation method. If the user selects "Yes", that is, selects the target activation method, the preset activation method corresponding to the target purpose is determined as the target activation method.

[0036] In one embodiment of this application, the electronic device 1 further includes a light sensor 81, an ultrasonic amplitude feedback device 82, and a temperature sensor 83. The light sensor 81 is used to sense the light intensity of the illumination end. The ultrasonic amplitude feedback device 82 is used to detect the amplitude of the ultrasonic waves generated by the ultrasonic end 30. The temperature sensor 83 is used to sense the ambient temperature of the platelet-rich plasma.

[0037] In one embodiment of this application, the execution end 60 controls the illumination parameters of the illumination end based on the illumination intensity sensed by the light sensor, controls the temperature control parameters of the temperature control end based on the temperature sensed by the temperature sensor, and controls the ultrasonic end to generate ultrasonic waves based on preset ultrasonic parameters.

[0038] It is understood that, in another embodiment of this application, the electronic device 1 may also include a container 10, a light-emitting end 20, an ultrasound end 30, a temperature control end 40, and an execution end 60, for exogenous activation of platelets based on a target activation method. The control end 50 and the interaction end 70 are provided by another independent electronic device, for interacting with the user to determine the target use of the platelet-rich plasma and the target activation method, and sending the target activation method to the electronic device 1.

[0039] In one embodiment of this application, the electronic device 1 may further include a heat dissipation end 84 for dissipating heat from the electronic device 1 or reducing the ambient temperature of the platelet-rich plasma. For example, the heat dissipation end 84 is a cooling fan.

[0040] See Figure 2 The diagram shown is a flowchart of a method for activating platelets to release growth factors and exosomes according to an embodiment of this application. The method is applied to the electronic device 1 in the above embodiment of this application, and the method includes: S101, based on the intended use of platelet-rich plasma, determines the target activation mechanism of platelet-rich plasma.

[0041] In one embodiment of this application, the target use of the platelet-rich plasma is received by the user through an interactive terminal, and the target activation mode of the platelet-rich plasma is determined by the control terminal based on the target use.

[0042] Specifically, the control terminal determines the preset activation method corresponding to the target purpose based on the correspondence between the purpose and the preset activation method and the target purpose, and determines the preset activation method corresponding to the target purpose as the target activation method.

[0043] In another embodiment of this application, the control terminal also sends the target activation method to the interactive terminal of the electronic device, and displays the target activation method for user confirmation through the interactive terminal. If the user does not select the target activation method, the control terminal receives the preset activation method input by the user and determines the preset activation method input by the user as the target activation method.

[0044] See Figure 3 The diagram illustrates the determination of a target activation method according to an embodiment of this application. The target application can be a department requiring platelet-rich plasma (PRP) or a body part where PRP is effective; for example, the target application could be orthopedics, dentistry, plastic surgery, or chronic wound care. After determining the target application of PRP based on user selection or input, the activation requirements for platelets are selected based on the user's selection, such as needing to activate more growth factors. Based on the activation requirements, exogenous activation is triggered. Based on the user's selection, it is determined whether to use the system-recommended activation method (i.e., the aforementioned target activation method). If the system-recommended activation method is used, it is sent to the execution end. If the system-recommended activation method is not used, the activation method is determined based on the user's selection, and the user-selected activation method is sent to the execution end.

[0045] S102, based on the target activation method, activate at least one of the light-emitting end, ultrasonic end, and temperature control end of the electronic device.

[0046] In one embodiment of this application, if the target activation method is light activation, the temperature control terminal and the light activation terminal are turned on. If the target activation method is ultrasonic activation, the temperature control terminal and the ultrasonic activation terminal are turned on. If the target activation method is temperature-controlled activation, the temperature control terminal is turned on. If the target activation method is both light and ultrasonic activation, the temperature control terminal, the light activation terminal, and the ultrasonic activation terminal are turned on. If the target activation method is both light and temperature-controlled activation, the temperature control terminal and the light activation terminal are turned on. If the target activation method is both ultrasonic and temperature-controlled activation, the temperature control terminal and the ultrasonic activation terminal are turned on. If the target activation method is a combination of light, ultrasonic, and temperature-controlled activation, the temperature control terminal, the light activation terminal, and the ultrasonic activation terminal are turned on.

[0047] S103, when the light end is turned on, irradiates platelet-rich plasma based on preset light parameters, and / or when the ultrasound end is turned on, performs ultrasound treatment on platelet-rich plasma based on preset ultrasound parameters, and / or when the temperature control end is turned on, adjusts the temperature of the environment in which the platelet-rich plasma is located based on preset temperature control parameters, so that platelets are activated and release growth factors and exosomes.

[0048] In one embodiment of this application, the preset illumination parameters include a preset wavelength, a preset light intensity range, and a preset irradiation duration. If the target activation method includes an illumination activation method, the illumination end is controlled to emit light of the preset wavelength, and the light intensity sensed by the light sensor of the electronic device is collected. If the light intensity sensed by the light sensor is not within the preset light intensity range, the wavelength of the light is adjusted until the light intensity sensed by the light sensor falls within the preset light intensity range, and the preset irradiation duration of the platelet-rich plasma is controlled by the illumination end.

[0049] In one embodiment of this application, the preset ultrasound parameters include a preset on-time, a preset frequency, and a preset duty cycle. If the target activation method includes an ultrasound activation method, the ultrasound terminal is controlled to generate ultrasound waves based on the preset frequency and the preset duty cycle, and the ultrasound waves propagate in the platelet-rich plasma for the preset on-time.

[0050] In one embodiment of this application, the preset temperature control parameter includes a first preset temperature range. Under all target activation modes, the temperature control terminal is controlled to maintain the ambient temperature of the platelet-rich plasma within the preset temperature range.

[0051] In one embodiment of this application, the preset temperature control parameters include a second preset temperature range and a corresponding preset duration. If the target activation method includes a temperature control activation method, the temperature control terminal is controlled to maintain the ambient temperature of the platelet-rich plasma within the second preset temperature range for the preset duration, and then the temperature control terminal is controlled to heat up to maintain the ambient temperature of the platelet-rich plasma within the first preset temperature range.

[0052] See Figure 4 The diagram shown illustrates parameter control corresponding to a target activation method provided in an embodiment of this application. The execution terminal executes the target activation method based on control commands sent by the control terminal.

[0053] If the target activation method is photoactivation, the preset illumination parameters include a preset wavelength and a preset light intensity range. For example, the preset wavelength range is 400-1200 nm (nanometers), and the preset light intensity range is 300-500 lx (lux). The illumination device emits light of the preset wavelength, and the light intensity sensed by the light sensor is collected. It is determined whether the light intensity sensed by the light sensor is within the preset light intensity range. If the light intensity sensed by the light sensor is not within the preset light intensity range, the illumination is adjusted until the light intensity sensed by the light sensor falls within the preset light intensity range. Then, the temperature control device is activated to maintain the ambient temperature of the platelet-rich plasma within the optimal activation range, for example, 30-37°C. At the ambient temperature corresponding to the preset light intensity range and the optimal activation range, the illumination device irradiates the platelet-rich plasma for a preset duration.

[0054] If the target activation method is ultrasound activation, the preset ultrasound parameters include a preset on-time, a preset frequency, and a preset duty cycle. For example, the preset frequency range is 20kHz-1MHz. The ultrasound device generates ultrasound waves based on the preset frequency and the preset duty cycle. The ultrasound waves propagate in the platelet-rich plasma. Then, the temperature control device is activated to maintain the ambient temperature of the platelet-rich plasma within the optimal activation range, for example, 30-37℃. At the ambient temperature corresponding to the optimal activation range, the ultrasound device generates ultrasound waves for the preset on-time.

[0055] In another embodiment of this application, the preset ultrasonic parameters may further include a preset amplitude range. During the generation of ultrasonic waves at the ultrasonic end, the amplitude of the ultrasonic waves detected by the ultrasonic amplitude feedback device is collected. If the amplitude of the ultrasonic waves does not fall within the preset amplitude range, the ultrasonic frequency or duty cycle is adjusted until the amplitude of the ultrasonic waves does not fall within the preset amplitude range.

[0056] If the target activation method is temperature-controlled activation, the preset temperature control parameters include multiple preset temperature control stages and the preset temperature range and duration for each stage. For example, multiple preset temperature control stages could be two separate stages. The first stage corresponds to a preset temperature range of 4-20℃, and the second stage corresponds to a preset temperature range of 30-37℃. In the first preset temperature control stage, the ambient temperature of the platelet-rich plasma is maintained within the preset temperature range of 4-20℃ for a first preset duration via the temperature control terminal. Then, in the second preset temperature control stage, the temperature is increased via the temperature control terminal to maintain the ambient temperature of the platelet-rich plasma within the optimal activation range (30-37℃) for a second preset duration.

[0057] If the target activation method is light and ultrasound activation, the preset light parameters include a preset wavelength and a preset light intensity range. For example, the preset wavelength range is 400-1200 nm (nanometers), and the preset light intensity range is 300-500 lx (lux). The preset ultrasound parameters include a preset on-time, a preset frequency, and a preset duty cycle. For example, the preset frequency range is 20 kHz-1 MHz. Specifically, the light source emits light of the preset wavelength, and the ultrasound source generates ultrasound waves based on the preset frequency and the preset duty cycle. The light intensity sensed by the light sensor is collected, and it is determined whether the light intensity sensed by the light sensor is within the preset light intensity range. If the light intensity sensed by the light sensor is not within the preset light intensity range, the light is adjusted until the light intensity sensed by the light sensor falls within the preset light intensity range. Then, the temperature control is activated to maintain the ambient temperature of the platelet-rich plasma in the optimal activation range, for example, the optimal activation range is 30-37°C. Under the ambient temperature corresponding to the preset light intensity range and the optimal activation interval, the light-emitting end irradiates platelet-rich plasma for a preset irradiation time, and the ultrasound-emitting end generates ultrasound waves for the preset on-time.

[0058] If the target activation method is light and temperature control activation, the preset light parameters include a preset wavelength and a preset light intensity range. For example, the preset wavelength range is 400-1200 nm, and the preset light intensity range is 300-500 lx. The preset temperature control parameters include multiple preset temperature control stages and the corresponding temperature range and duration for each stage. For example, multiple preset temperature control stages may be two separate stages. The first stage corresponds to a preset temperature range of 4-20°C, used to suppress pre-activation, while the second stage corresponds to a preset temperature range of 30-37°C, used to trigger controlled release and prevent premature decay. Specifically, in the first preset temperature control stage, the temperature is maintained at a low temperature for a first preset duration. Then, the light source is controlled to activate the preset wavelength light. The light intensity sensed by the light sensor is collected, and it is determined whether the light intensity sensed by the light sensor is within the preset light intensity range. If the light intensity sensed by the light sensor is not within the preset light intensity range, the light is adjusted until the light intensity sensed by the light sensor falls within the preset light intensity range. Then, in the second preset temperature control stage, the ambient temperature of the platelet-rich plasma is maintained within the optimal activation range (30-37℃) for a second preset duration by heating the temperature control end. The platelet-rich plasma is then irradiated for a preset duration within the preset light intensity range and the ambient temperature corresponding to the optimal activation range.

[0059] If the target activation method is light, ultrasound, or temperature control activation, the preset light parameters include preset wavelength and preset light intensity range. For example, the preset wavelength range is 400-1200 nm (nanometers), and the preset light intensity range is 300-500 lx (lux). The preset ultrasound parameters include preset on-time, preset frequency, and preset duty cycle. For example, the preset frequency range is 20 kHz-1 MHz. The preset temperature control parameters include multiple preset temperature control stages and the corresponding temperature range and duration for each stage. For example, multiple preset temperature control stages could be two separate preset temperature control stages, with the first stage corresponding to a preset temperature range of 4-20°C and the second stage corresponding to a preset temperature range of 30-37°C.

[0060] Specifically, in the first preset temperature control stage, the temperature is maintained at a low temperature for a first preset duration by the temperature control terminal. Then, the light irradiation terminal emits light of a preset wavelength, and the ultrasound terminal generates ultrasound waves based on the preset frequency and preset duty cycle. The light intensity sensed by the light sensor is collected, and it is determined whether the light intensity sensed by the light sensor is within the preset light intensity range. If the light intensity sensed by the light sensor is not within the preset light intensity range, the light is adjusted until the light intensity sensed by the light sensor falls within the preset light intensity range. Then, in the second preset temperature control stage, the temperature of the platelet-rich plasma is maintained in the optimal activation range (30-37℃) for a second preset duration by the temperature control terminal. Within the preset light intensity range and the ambient temperature corresponding to the optimal activation range, the light irradiation terminal irradiates the platelet-rich plasma for a preset irradiation time, and the ultrasound terminal generates ultrasound waves for a preset duration.

[0061] This application's embodiments are based on a photo-activation method, which can control different light wavelengths to activate platelets and induce the release of required growth factors according to the different growth factors needed by different patients. Based on a photo- and ultrasound-based activation method, ultrasound and photo-activation complement each other, covering a wider range of growth factors and increasing the release of exosomes. Based on a temperature-controlled activation method, the temperature curve can be adjusted to flexibly match acute repair (rapid warming) or long-term regeneration (stepwise warming). Based on photo-, ultrasound, and temperature-controlled activation methods, a more comprehensive and rapid activation of platelets is achieved, enabling the release of required growth factors in large quantities. This application's embodiments, through real-time detection and control of light intensity and temperature, ensure safe and effective platelet activation within the optimal range, avoiding over-activation or incomplete activation.

[0062] See Figure 5The diagram shown is a hardware structure schematic of an electronic device provided in an embodiment of this application. The method for activating platelets to release growth factors and exosomes provided in this embodiment is applied in an electronic device 1. The electronic device 1 includes, but is not limited to, a processor 110 and a memory 120 connected via a communication bus 130. For example, the processor 110 may include the control terminal and the execution terminal described above. Figure 5 This is merely an example of an electronic device and does not constitute a limitation thereof. In other embodiments, the electronic device may include more components than those shown in the figure.

[0063] The memory 120 may include one or more random access memory (RAM) and one or more non-volatile memory (NVM). The RAM can be directly read and written by the processor 110 and can be used to store executable programs (such as machine instructions) of the operating system or other running programs, as well as user and application data. The RAM may include static random access memory (SRAM), dynamic random access memory (DRAM), synchronous dynamic random access memory (SDRAM), double data rate synchronous dynamic random access memory (DDR SDRAM), etc.

[0064] Non-volatile memory can also store executable programs and user and application data, and can be pre-loaded into random access memory for direct reading and writing by the processor 110. Non-volatile memory can include disk storage devices and flash memory.

[0065] The memory 120 is used to store one or more computer programs. The one or more computer programs are configured to be executed by the processor 110. The one or more computer programs include a plurality of instructions that, when executed by the processor 110, enable a method for activating platelets to release growth factors and exosomes, which is executed on the electronic device 1.

[0066] In other embodiments, the electronic device 1 further includes an external memory interface for connecting to an external memory to expand the storage capacity of the electronic device 1.

[0067] Processor 110 may include one or more processing units, such as an application processor (AP), a modem processor, a graphics processing unit (GPU), an image signal processor (ISP), a controller, a video codec, a digital signal processor (DSP), a baseband processor, and / or a neural network processing unit (NPU). These different processing units may be independent devices or integrated into one or more processors.

[0068] The processor 110 provides computing and control capabilities, for example, the processor 110 is used to execute computer programs or program instructions stored in the memory 120 to implement the above-described method of activating platelets to release growth factors and exosomes.

[0069] The communication bus 130 is used to provide a channel for communication between the memory 120 and the processor 110 in the electronic device 1.

[0070] It is understood that the structures illustrated in the embodiments of this application do not constitute a specific limitation on the electronic device 1. In other embodiments of this application, the electronic device 1 may include more or fewer components than illustrated, or combine some components, or split some components, or have different component arrangements. The illustrated components may be implemented in hardware, software, or a combination of software and hardware.

[0071] This application also provides a computer storage medium storing computer instructions. When the computer instructions are executed on an electronic device 1, the electronic device 1 performs the aforementioned related method steps to realize the method of activating platelets to release growth factors and exosomes as described in the above embodiments.

[0072] This application also provides a computer program product that, when run on a computer, causes the computer to perform the aforementioned steps to achieve the method of activating platelets to release growth factors and exosomes as described in the above embodiments.

[0073] In addition, embodiments of this application also provide an apparatus, which may specifically be a chip, component or module. The apparatus may include a connected processor and a memory; wherein, the memory is used to store computer execution instructions, and when the apparatus is running, the processor may execute the computer execution instructions stored in the memory to cause the chip to execute the method of activating platelets to release growth factors and exosomes in the above method embodiments.

[0074] In this application, the electronic devices, computer storage media, computer program products or chips provided in the embodiments are all used to execute the corresponding methods provided above. Therefore, the beneficial effects they can achieve can be referred to the beneficial effects in the corresponding methods provided above, and will not be repeated here.

[0075] Through the above description of the embodiments, those skilled in the art can clearly understand that, for the sake of convenience and brevity, only the division of the above functional modules is used as an example. In actual applications, the above functions can be assigned to different functional modules as needed, that is, the internal structure of the device can be divided into different functional modules to complete all or part of the functions described above.

[0076] In the several embodiments provided in this application, it should be understood that the disclosed apparatus and methods can be implemented in other ways. For example, the apparatus embodiments described above are merely illustrative; for instance, the division of modules or units is only a logical functional division, and in actual implementation, there may be other division methods. For example, multiple units or components may be combined or integrated into another device, or some features may be ignored or not executed. Furthermore, the mutual coupling or direct coupling or communication connection shown or discussed may be through some interfaces; the indirect coupling or communication connection between devices or units may be electrical, mechanical, or other forms.

[0077] The units described as separate components may or may not be physically separate. A component shown as a unit can be one or more physical units; that is, it can be located in one place or distributed in multiple different locations. Some or all of the units can be selected to achieve the purpose of this embodiment according to actual needs.

[0078] Furthermore, the functional units in the various embodiments of this application can be integrated into one processing unit, or each unit can exist physically separately, or two or more units can be integrated into one unit. The integrated unit can be implemented in hardware or as a software functional unit.

[0079] If the integrated unit is implemented as a software functional unit and sold or used as an independent product, it can be stored in a readable storage medium. Based on this understanding, the technical solutions of the embodiments of this application, or the parts or all or part of the technical solutions that contribute to the prior art, can be embodied in the form of a software product. The software product is stored in a storage medium and includes several instructions to cause a device (which may be a microcontroller, chip, etc.) or processor to execute all or part of the steps of the methods of the various embodiments of this application. The aforementioned storage medium includes various media capable of storing program code, such as USB flash drives, portable hard drives, read-only memory (ROM), random access memory (RAM), magnetic disks, or optical disks.

[0080] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of this application and are not intended to limit it. Although this application has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of this application without departing from the spirit and scope of the technical solutions of this application.

Claims

1. A method for activating platelets to release growth factors and exosomes, applied to electronic devices, characterized in that, The method includes: Based on the intended use of platelet-rich plasma, the target activation mode of the platelet-rich plasma is determined; Based on the target activation method, at least one of the light-emitting end, ultrasonic end, and temperature-control end of the electronic device is activated. When the light-emitting end is turned on, the platelet-rich plasma is irradiated based on preset light-emitting parameters, and / or when the ultrasound end is turned on, the platelet-rich plasma is subjected to ultrasound treatment based on preset ultrasound parameters, and / or when the temperature control end is turned on, the temperature of the environment in which the platelet-rich plasma is located is adjusted based on preset temperature control parameters, so that platelets are activated and release growth factors and exosomes.

2. The method as described in claim 1, characterized in that, The method further includes: Receive user input regarding the intended use of the platelet-rich plasma; The target activation method of the platelet-rich plasma is determined based on the user's input of the intended use of the platelet-rich plasma. The target activation method is determined from a plurality of preset activation methods, including light activation, ultrasound activation, temperature control activation, light and ultrasound activation, light and temperature control activation, ultrasound and temperature control activation, and light, ultrasound and temperature control activation.

3. The method as described in claim 2, characterized in that, The determination of the target activation mode of the platelet-rich plasma based on the user-inputted target use includes: Based on the correspondence between the purpose and the preset activation method, and the target purpose, the preset activation method corresponding to the target purpose is determined, and the preset activation method corresponding to the target purpose is determined as the target activation method.

4. The method as described in claim 2, characterized in that, The method of determining the target activation mode of platelet-rich plasma based on the target use of the platelet-rich plasma input by the user also includes: The target activation method is sent to the interactive terminal of the electronic device; The target activation method is displayed to the user for confirmation through the interactive terminal. If the user does not select the target activation method, the preset activation method input by the user is received. The user-input preset activation method is determined as the target activation method.

5. The method as described in claim 1, characterized in that, The preset illumination parameters include a preset wavelength, a preset light intensity range, and a preset irradiation duration. Irradiating the platelet-rich plasma based on these preset illumination parameters when the illumination end is turned on includes: Control the light source to emit light of the preset wavelength; The light intensity sensed by the light sensor of the electronic device is collected. If the light intensity sensed by the light sensor is not within the preset light intensity range, the wavelength of the light is adjusted until the light intensity sensed by the light sensor falls within the preset light intensity range. The preset irradiation time for irradiating the platelet-rich plasma by the light source is controlled.

6. The method as described in claim 1, characterized in that, The preset ultrasound parameters include preset on-time, preset frequency, and preset duty cycle. The step of performing ultrasound processing on the platelet-rich plasma based on the preset ultrasound parameters when the ultrasound terminal is on includes: The ultrasound terminal is controlled to generate ultrasound waves based on the preset frequency and the preset duty cycle. The ultrasound waves propagate in the platelet-rich plasma for the preset on-time.

7. The method as described in claim 1, characterized in that, The preset temperature control parameters include a first preset temperature range, and the step of adjusting the temperature of the platelet-rich plasma environment based on the preset temperature control parameters when the temperature control terminal is turned on includes: The temperature control terminal maintains the ambient temperature of the platelet-rich plasma within the preset temperature range.

8. The method as described in claim 7, characterized in that, The preset temperature control parameters include a second preset temperature range and a corresponding preset duration. If the target activation method includes a temperature control activation method, the step of adjusting the temperature of the platelet-rich plasma environment based on the preset temperature control parameters when the temperature control terminal is turned on further includes: The temperature control terminal is used to maintain the ambient temperature of the platelet-rich plasma within the second preset temperature range for the preset duration. The temperature control terminal is heated to maintain the ambient temperature of the platelet-rich plasma within the first preset temperature range.

9. An electronic device, characterized in that, The electronic device includes a memory and a processor: The memory is used to store program instructions; The processor is configured to read and execute the program instructions stored in the memory, and when the program instructions are executed by the processor, cause the electronic device to perform the method of activating platelets to release growth factors and exosomes as described in any one of claims 1 to 8.

10. A computer storage medium, characterized in that, The computer storage medium stores program instructions that, when executed on an electronic device, cause the processor of the electronic device to perform the method of activating platelets to release growth factors and exosomes as described in any one of claims 1 to 8.

Images